Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Jordan J. Wright"'
Autor:
John Virostko, Richard C Craddock, Jonathan M Williams, Taylor M Triolo, Melissa A Hilmes, Hakmook Kang, Liping Du, Jordan J Wright, Mara Kinney, Jeffrey H Maki, Milica Medved, Michaela Waibel, Thomas W H Kay, Helen E Thomas, Siri Atma W Greeley, Andrea K Steck, Daniel J Moore, Alvin C Powers
Publikováno v:
PLoS ONE, Vol 16, Iss 8, p e0256029 (2021)
Magnetic resonance imaging (MRI) has detected changes in pancreas volume and other characteristics in type 1 and type 2 diabetes. However, differences in MRI technology and approaches across locations currently limit the incorporation of pancreas ima
Externí odkaz:
https://doaj.org/article/dbc9dc62256a40189372bb1641b4d5fe
Autor:
Jordan J. Wright, Jonathan M. Williams, Lisa R. Letourneau-Freiberg, Balamurugan Kandasamy, Demetra Reyes, Anastasia Gant Kanegusuku, Louis Philipson, Siri Atma W. Greeley, Melissa A. Hilmes, Alvin C. Powers, John Virostko, Daniel J. Moore
Publikováno v:
Diabetes Care. 46:773-776
OBJECTIVE To determine the mechanism of reduced pancreas size in type 1 diabetes and the significance of islet-derived insulin in pancreatic growth. RESEARCH DESIGN AND METHODS Using a validated and standardized MRI protocol, we measured pancreas vol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c645df101838ebb2704b5ce5da4c6465
https://doi.org/10.2337/dc22-2082
https://doi.org/10.2337/dc22-2082
Publikováno v:
AACE Clinical Case Reports, Vol 5, Iss 1, Pp e31-e34 (2019)
ABSTRACT: Objective: Hemoglobin A1c (HbA1c) is a useful tool for the diagnosis and management of diabetes mellitus and generally an excellent marker of overall glycemic control for the preceding 8 to 12 weeks; however, the test is not without its pit
Externí odkaz:
https://doaj.org/article/a95e68e272544326af863a7329915a24
Autor:
Jordan J Wright, Aidan Dulaney, Jonathan M Williams, Melissa A Hilmes, Liping Du, Hakmook Kang, Alvin C Powers, Daniel J Moore, John Virostko
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism.
Context Individuals with type 1 diabetes (T1D) have a smaller pancreas, but longitudinal changes in pancreas size and shape are unclear. Objective We monitored changes in pancreas size and shape after diagnosis with T1D. Design We conducted a prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2dd6564233bce01ec8656e245b9b0e7
https://doi.org/10.1210/clinem/dgad150
https://doi.org/10.1210/clinem/dgad150
Publikováno v:
The Oncologist. 27:e967-e969
Immune checkpoint inhibitor (ICI)-induced hypophysitis is an immune-mediated pituitary inflammation that tends to cause long-term pituitary deficiency. Management of ICI-induced hypophysitis includes corticosteroids for acute inflammation and long-te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9188520c39f2852e4301bf88bb54ccd2
https://doi.org/10.1093/oncolo/oyac220
https://doi.org/10.1093/oncolo/oyac220
Autor:
Jordan J Wright, Douglas B Johnson
Publikováno v:
The Journal of clinical endocrinology and metabolism.
Immune checkpoint inhibitors (ICI) are cancer therapies that are approved for use in at least 19 different cancers. They function by stimulating immune cell responses against cancer, and their toxicities comprise a host of autoinflammatory syndromes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4579e9c49b2eb16593c0fbcc063d0dff
https://pubmed.ncbi.nlm.nih.gov/36481794
https://pubmed.ncbi.nlm.nih.gov/36481794
Autor:
JORDAN J. WRIGHT, JONATHAN M. WILLIAMS, SIRI ATMA W. GREELEY, ALVIN C. POWERS, JOHN VIROSTKO, DANIEL J. MOORE
Publikováno v:
Diabetes. 71
Individuals with new-onset type 1 diabetes (T1D) and those at risk for T1D have a smaller pancreas. The reason for the reduced pancreas size and acinar cell number in T1D is not known, with possible explanations being a direct effect of insulin defic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bb41ba7ee99b0b154aacc479aec9bed
https://doi.org/10.2337/db22-206-or
https://doi.org/10.2337/db22-206-or
Autor:
JOHN VIROSTKO, JORDAN J. WRIGHT, JONATHAN M. WILLIAMS, MELISSA A. HILMES, TAYLOR M. TRIOLO, HALI C. BRONCUCIA, LIPING DU, HAKMOOK KANG, WILLIAM E. RUSSELL, LOUIS H. PHILIPSON, THOMAS KAY, HELEN E. THOMAS, SIRI ATMA W. GREELEY, ANDREA STECK, ALVIN C. POWERS, DANIEL J. MOORE
Publikováno v:
Diabetes. 71
Pancreas size, as measured by MRI, is smaller at the onset of T1D and in individuals at risk for T1D. To determine whether pancreas MRI predicts T1D progression, we measured pancreas size and shape longitudinally in Type 1 Diabetes TrialNet Pathway t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b05c7d1263a3e0d0e56a82c9b241248
https://doi.org/10.2337/db22-35-or
https://doi.org/10.2337/db22-35-or
Publikováno v:
Nat Rev Endocrinol
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac4ab4a8de94651358e4e4b342e8b5a
https://doi.org/10.1038/s41574-021-00484-3
https://doi.org/10.1038/s41574-021-00484-3
Autor:
Margaret L. Axelrod, Wouter C. Meijers, Elles M. Screever, Juan Qin, Mary Grace Carroll, Xiaopeng Sun, Elie Tannous, Yueli Zhang, Ayaka Sugiura, Brandie C. Taylor, Ann Hanna, Shaoyi Zhang, Kaushik Amancherla, Warren Tai, Jordan J. Wright, Spencer C. Wei, Susan R. Opalenik, Abigail L. Toren, Jeffrey C. Rathmell, P. Brent Ferrell, Elizabeth J. Phillips, Simon Mallal, Douglas B. Johnson, James P. Allison, Javid J. Moslehi, Justin M. Balko
Publikováno v:
Nature, vol 611, iss 7937
Nature, 611(7937), 818-826. Nature Publishing Group
Nature, 611. Nature Publishing Group
Nature, 611(7937), 818-826. Nature Publishing Group
Nature, 611. Nature Publishing Group
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy1. The pathogenesis of ICI-associated myocarditis (ICI-MC) is poorly un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a9e654e239d5a2d33ccbae075f71de
https://doi.org/10.1038/s41586-022-05432-3
https://doi.org/10.1038/s41586-022-05432-3